All News
Filter News
Found 605 articles
-
With $96 million in Series A financing, Cajal Neuroscience launched Tuesday to develop drug candidates to target neurodegeneration in Alzheimer’s and Parkinson’s diseases.
-
A second patient death has been linked to the Phase III clinical trial of Eisai and Biogen’s investigational Alzheimer's drug lecanemab, according to the journal Science.
-
Alzheon to Present Industry-Leading Biomarker, Brain Preservation, and Clinical Effects with Oral ALZ-801 (Valiltramiprosate) at 15th Annual Clinical Trials in Alzheimer’s Disease Conference
11/22/2022
Alzheon, Inc. today announced that it will be presenting new clinical trial data at the 15th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference to be held from November 29 – December 2, 2022 in San Francisco, CA, USA.
-
When Roche announced that gantenerumab failed to meet the primary endpoint in two Phase III studies, several of its competitors saw their stocks rise - including Biogen and Eisai.
-
ALZHEIMER'S ASSOCIATION STATEMENT ON GANTENERUMAB PHASE 3 TOPLINE DATA RELEASE
11/14/2022
The Alzheimer's Association is disappointed by the topline Phase 3 data reported today by Genentech and Roche from the GRADUATE Phase 3 global clinical trials of gantenerumab.
-
With diagnostics for Alzheimer's already approved and therapeutics in late-stage clinical trials, the next hurdle is to translate these advances into clinical practice. The Davos Alzheimer's Collaborative is working on it.
-
The FDA released guidelines Thursday in an attempt to clarify processes for assessing a drug candidate’s efficacy while examining several endpoints, simultaneously.
-
While Biogen and Eisai's recent lecanemab data breathed new life into the anti-amyloid approach, experts say combination therapies will likely play a significant role in treating Alzheimer's disease.
-
The FDA’s approval of Amylyx's Relyvrio has ignited the growing momentum in the ALS space. BioSpace spoke with Amylyx co-CEOs Justin Klee and Josh Cohen and leading ALS researcher Dr. Merit Cudkowicz.
-
Biogen and Eisai's lecanemab win this week provides an opportunity to stop and consider whether science is closer to a cure or symptom management for Alzheimer's disease.
-
The HHS Office of Inspector General found that of 278 accelerated approvals between 1992 and 2021, 104 had incomplete confirmatory trials, according to a report issued Thursday.
-
Eisai and Biogen announced positive data from a Phase III trial in Alzheimer’s of its drug lecanemab. Still, questions remain about the drug's implications for the future of Alzheimer's treatment.
-
Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease
9/20/2022
Alzheon, Inc. reported statistically significant and clinically relevant plasma biomarker reduction, robust preservation of brain volume, and positive memory effects in Alzheimer’s patients following 12 months of treatment with investigational agent ALZ-801 in its Phase 2 biomarker trial.
-
Alzheon Appoints Glenn Pauly as Head of Commercial
9/20/2022
Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease and other neurodegenerative disorders, announced the appointment of Glenn E. Pauly as Head of Commercial.
-
Biogen expects to lay off a potential 1,000 staffers in an effort to cut about $1 billion in costs, according to The Boston Globe, while 10x Genomics and Talis Biomedical also cut staff.
-
Researchers have found that two common viruses—the varicella zoster and herpes simplex viruses—likely constitute a pathway that leads to Alzheimer's disease.
-
Roche signed a big $6 billion-plus collaboration deal with Poseida on blood cancers while its partner, AC Immune, parsed failed data on an Alzheimer’s drug to suggest a positive spin.
-
ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference
8/2/2022
ProMIS Neurosciences Inc. announced details of its poster presentation at the annual Alzheimer’s Association International Conference being held from July 31-August 4, 2022 at the San Diego Convention Center, San Diego California and online.
-
The ongoing AAIC 2022 in San Diego has delivered positive news for the AD space. We look at updates from Vivoryon, Anavex and Argentinian scientists below.
-
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
7/31/2022
Vivoryon Therapeutics N.V. announced the presentation of preclinical data on the Company's N3pE amyloid-targeting molecules at the prestigious Alzheimer's Association International Conference in San Diego.